Crystalys Therapeutics
Clinical trials sponsored by Crystalys Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for gout sufferers: drug dotinurad targets high uric acid Results expected Jul 2027 (estimated)
-
New gout drug aims to crush uric acid and shrink painful tophi
Disease control Recruiting nowThis study tests a new medicine called dotinurad against the standard drug allopurinol in 250 adults with tophaceous gout (gout with hard lumps under the skin). The main goal is to see if dotinurad lowers uric acid levels better after 24 weeks. Researchers will also check if toph…
Phase 3 • Sponsor: Crystalys Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New gout drug aims to beat allopurinol in major trial
Disease control Recruiting nowThis study tests a new medicine called dotinurad against the standard drug allopurinol for lowering uric acid in adults with gout. About 500 people who have had at least two gout flares in the past year will take either dotinurad or allopurinol for 24 weeks. The main goal is to s…
Phase 3 • Sponsor: Crystalys Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for gout sufferers: drug dotinurad targets high uric acid
Disease control Recruiting nowThis study tests a new drug called dotinurad in 90 adults with gout who cannot take common medications like allopurinol or have not responded to other treatments. The goal is to see if dotinurad can safely lower uric acid levels over 24 weeks. Participants are randomly assigned t…
Phase 2 • Sponsor: Crystalys Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC